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Technology  transfer  is a  promising  approach  to increase  vaccine  production  at  an  affordable  price  in
developing  countries.  In  the  case  of inﬂuenza,  it is  imperative  that  developing  countries  acquire  the
technology  to produce  pandemic  vaccines  through  the  transfer  of  know-how,  as  this  will  be  the  only  way
for  the  majority  of  these  countries  to  face  the  huge  demand  for vaccine  created  by  inﬂuenza  pandemics.
Access  to  domestically  produced  inﬂuenza  vaccine  in  such  health  crises  is  thus  an  important  national
defence  strategy.  However,  technology  transfer  is  not  a  simple  undertaking.  It requires  a committed
provider  who  is  willing  to  transfer  a complete  production  process,  and  not  just  the  formulation  and  ﬁll-
ﬁnish  parts  of  the  process.  It  requires  a  recipient  with  established  experience  in vaccine  production  for
human  use  and  the ability  to conduct  research  into  new  developments.  In  addition,  the  country  of  the
recipient  should  preferably  have  sufﬁcient  ﬁnancial  resources  to  support  the undertaking,  and  an  internal
market  for  the  new  vaccine.  Technology  transfer  should  create  a solid  partnership  that  results  in  the  joint
development  of  new  competency,  improvements  to  the  product,  and  to further  innovation.
The  Instituto  Butantan–sanoﬁ  pasteur  partnership  can  be  seen  as a model  for  successful  technology
transfer  and  has  led  to  the  technological  independence  of  the  Instituto  Butantan  in the  use  a  strategic
public  health  tool.. Introduction
In 2000, the Ministry of Health decided to provide inﬂuenza vac-
ination free of charge to individuals over 60 years of age, patients
ith chronic diseases, and health-care personnel. The Instituto
utantan – an arm of the São Paulo Ofﬁce of Health – was charged
o develop, produce and register the seasonal vaccine needed to
mplement this policy decision. The yearly demand for seasonal
nﬂuenza vaccine was estimated at 25 million doses, to be deployed
t 25 000 health centres across the country. A signiﬁcant chal-
enge to this enterprise was the short time available to import
he approved vaccine strains and control reagents from the World
ealth Organization (WHO), prepare production banks, and carry
ut the required quality control tests in time for the annual south-
rn hemisphere inﬂuenza season that starts in most of Brazil in
pril.
In parallel, the highly pathogenic avian inﬂuenza outbreak that
hreatened many countries in Asia in 2003 was a powerful argu-
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ment for Brazil to increase its inﬂuenza pandemic preparedness.
At that time, it was  anticipated that countries without seasonal
inﬂuenza production capacity, or existing contracts for the sup-
ply of vaccine, may  have to wait over a year before sufﬁcient
pandemic vaccine became available to immunize their population
[1,2].
To address these issues, Brazil sought a technology transfer part-
nership to construct a dedicated inﬂuenza vaccine production plant
and, in the interim, to formulate and ﬁnish monovalent bulk vaccine
supplied by an international vaccine producer, who would agree to
become the technology provider.
The objectives were to produce 25 million doses of seasonal vac-
cine per year and to create a stockpile of H5N1 vaccine for use at
the onset of a potential inﬂuenza pandemic. This paper describes
progress towards these goals and discusses Butantan’s experience
of the transfer of a complete production process.
2. Selection of the best technology transfer partner
Open access under CC BY-NC-ND license.As  the production of inactivated inﬂuenza vaccine in embry-
onated eggs is a very standardized process, there is no regulatory
uncertainty for manufacturers embarking on such production
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also called vaccine viruses) are generated and tested under the
egis of WHO, and that the plant complies with Good Man-
facturing Practice (GMP). Moreover, the basic technology to
row viruses in fertilized hen eggs is well known to virology
aboratories and producers of veterinary and human vaccines,
nd production technology does not vary with the inﬂuenza
erotype.
For Butantan, a technology supplier would also need to take
ccount of the ﬁnancial constraints of a not-for-proﬁt organiza-
ion. For example, the Institute would only be able to pay for the
ulk vaccine upon transfer of funds from the Ministry of Health
nd approval of the vaccine by the National Control Laboratory, i.e.
onths after receipt of this bulk in Brazil. Exchange rate ﬂuctua-
ions add to this concern.
Butantan  selected sanoﬁ pasteur (previously Sanoﬁ Aventis) as
ts bulk vaccine provider and technology transfer partner for egg-
ased inactivated split seasonal inﬂuenza vaccine and whole virion
djuvanted H5N1 vaccine. Two reasons guided this choice: ﬁrst,
anoﬁ pasteur’s extensive experience in large-scale inﬂuenza vac-
ine production, and second, the long-standing relationship of this
ompany with Brazil. Indeed, in 1975 it was the only company to
ccept the challenge to build temporary facilities for the supply
f meningococcal serogroup A/C vaccines to control a widespread
pidemic in major Brazilian cities.
A production plant was designed to process 125000 eggs per
ay to allow for the production of up to 25 million doses of non-
djuvanted trivalent seasonal vaccine. The technology transfer
olution agreed by both parties – in addition to addressing logistic,
ime and ﬁnancial constraints – comprised oversight of the produc-
ion plant design and selection of equipment (partly produced in
razil), supervision of the construction of the plant and its valida-
ion, as well as assistance in the selection of an adequate source of
ggs and training of senior staff.
. Construction of the large production plant for seasonal
nﬂuenza
The  Ministry of Health, under an agreement concluded with
utantan in 2004, provided US$ 10 million to purchase the basic
quipment, and the State of São Paulo Ofﬁce of Health agreed to
und the construction of the plant, estimated at US$ 20 million.
igniﬁcant delays were incurred because of a legal challenge dur-
ng the tender process, difﬁculties experienced by the construction
ompany, and the emergence of highly pathogenic H5N1 avian
nﬂuenza. The latter required Butantan to upgrade its containment
acilities and to identify and implement a technical solution to pro-
ess residual egg shells and chicken embryos so that they could not
e used for animal feed. The cost of the plant thus increased to US$
5 million.
As  with its other non-live vaccines, Butantan intends to trans-
er the monovalent inactivated bulk vaccine produced in the new
roduction plant to its central formulation and ﬁlling plants. Two
lling lines – one automated and the other manual – can sterilize,
ll, cap, label and control 26 000 vials per hour. To save on transport
nd cold-room storage, each ﬁll-ﬁnished vial will contain 10 doses.
Sanoﬁ Pasteur fulﬁlled all the terms of the technology transfer
greement, including the provision of expert advice, site visits and
raining for key staff. Sanoﬁ experts were also instrumental in over-
eeing the building of a large additional fertilized egg production
arm near to Butantan.
In  September 2010, after ﬁnal validation by sanoﬁ pasteur, the
nﬂuenza production plant was ready for production. Starting from
011, Butantan intends to produce 20–25 million doses of trivalent
outhern hemisphere seasonal vaccine per year. The development
nd registration of an adjuvanted formulation would allow for the9S (2011) A12– A15 A13
production of signiﬁcantly more vaccine, as reported below. This
is particularly important in view of the fact that non-adjuvanted
H5N1 split inactivated inﬂuenza vaccine is poorly immunogenic
and requires immunization of vaccines twice with very high doses
of haemagglutinin (HA) antigen (90 g compared to 15 g for sea-
sonal vaccine). In order to alleviate this problem – i.e. to “spare”
antigen in case of a pandemic and maximize the number of per-
sons who can be immunized – multinational vaccine manufacturers
have developed much more immunogenic H5N1 adjuvanted vac-
cine formulations.
4.  Establishment of a “pandemic” inﬂuenza vaccine pilot
plant
In  2008, the Instituto Butantan was selected, along with ﬁve
other developing country vaccine manufacturers, to receive ﬁnan-
cial and technical support from WHO  as part of an initiative to
increase global production capacity for pandemic inﬂuenza vaccine
[3]. The grant was for the construction and partial equipment of a
pilot plant – a standard procedure for all new projects at Butantan
– to manufacture experimental lots of H5N1 inﬂuenza vaccine, and
for the training of key staff of the new production plant. The pilot
plant would allow the development of basic technology to produce
small vaccine lots for evaluation in animal models and, if produced
under GMP, for a Phase 1 clinical trial to ascertain whether the
safety and immunogenicity results obtained in human volunteers
was similar to those obtained in animals.
The pilot plant was  rapidly installed in an existing building
adapted for GMP  and equipped using funding from WHO, the
Brazilian Ministry of Health, the São Paulo State Foundation, FINEP
(a Federal Granting Organization), and CNPq (National Research
Council). Additional funds invested by the Butantan Foundation
were largely used to recruit new staff, who were later relocated
to the large production plant.
In order to train the technical production staff, and to con-
duct the ﬁrst adjuvantation assays [4] of inﬂuenza vaccine
produced in Butantan, we  ﬁrst produced small lots of an H3N2
serotype vaccine. We  then prepared master and working seed
banks for H5N1 reference vaccine viruses (A/H5N1/Vietnam/2003
and  A/H5N1/Indonesia/2005). A chromatography procedure was
developed to purify whole virion H5N1. This allowed us to eval-
uate the yields for both split and whole virion vaccine, the
immunogenicity of the H5N1 candidate vaccine and the antigen-
sparing potential of several adjuvants in mice. Using 10 g of
Butantan’s MPLA (Monophosphoryl lipid A) or alum, we demon-
strated that it was  possible to successfully immunize mice
with 3.75 g of HA with a balanced humoral/cellular response
[5].
To date we have produced seven lots of experimental H3N2 and
three lots of H5N1. HA antigen sufﬁcient to enable the rapid formu-
lation of 20 000 doses of H5N1 vaccine were produced and stored
at 4 ◦C.
The unexpected spread of the A/H1N1 inﬂuenza pandemic in
2009 moved Butantan’s priority to this novel virus serotype. New
master and working virus seed banks were produced, antigen-
sparing of our MPLA adjuvant tested in mice, and a small Phase
1 clinical assay carried out in human volunteers. This trial was sup-
ported by the Butantan Foundation, the Children’s Hospital, and the
Campus Hospital of the University of São Paulo.
Table 1 shows the yield and purity of the H3N2, H5N1 and H1N1
candidate vaccines produced in the pilot plant over the period
2007–2009. The pilot laboratory has now become a permanent
facility to develop and test technology improvements and to pro-
duce master and working virus seed lots. A quality control section
will also be incorporated into the laboratory in the coming months.
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Table 1
Comparison of yield and puriﬁcation of inﬂuenza serotypes.
Viral strain A/Panama 007/99 H3N2 (split) NIBRG-14 H5N1 (split) NIBRG-14 H5N1 (whole virion) NYMC X179 A/H1N1 2009 (split)
Number of lots 6 10 17 1
Number of 15 g doses per egg 2.09 0.57 1.12 1.53














































hng ovalbumin/dose 20.47 15.4 
ng ovalbumin/g protein 0.97 11.33 
. Matching Brazilian inﬂuenza production capacity to
volving  public health needs
.1. Demographics
The population of Brazil is changing fast. From 184 million when
he inﬂuenza vaccine project started in 2004, the population is
xpected to reach 204 million in 2040. Demographically, the com-
ng years are expected to show a reduced demand for paediatric
accines due to lower birth rates. On the other hand, the increase in
ife expectancy means that the population over 60 years of age will
epresent about 40% of the total population in 2040. This evolution
as an important bearing on vaccine needs and production plant
apacity. Indeed, using 15 g of antigen per dose as anticipated for
 non-adjuvanted split inactivated vaccine, Butantan would not be
ble to meet the demand of the Ministry of Health for seasonal
nﬂuenza vaccine.
.2.  Northern or southern hemisphere vaccine formulations
Butantan’s production plant will operate for 4–6 months per
ear to produce southern hemisphere inﬂuenza vaccine, and would
emain idle for a full semester. It could therefore be envisaged to
roduce the northern hemisphere formulation during these inac-
ive months, which could be provided to other governments for
mmunization of their target groups, in exchange for southern
emisphere vaccine. Approval for this strategy remains to be sought
rom the technology provider (sanoﬁ pasteur).
There are further complexities in the timing and formulation of
nﬂuenza vaccine in Brazil. Vaccination in the north and north-east
urrently takes place as elsewhere in the country in April, yet this is
our months after the local seasonal inﬂuenza peak. Analysis of an
pidemiological survey suggests that vaccination should take place
arlier in this region. The exact transmission pathway that deter-
ines the origin of the virus is not clearly understood, nor the onset
f a signiﬁcant drop in temperature that sparks inﬂuenza incidence.
ven if we could use the northern hemisphere formulation in this
egion, our inability to meet the demand for the southern hemi-
phere vaccine would not change, as the north and north-eastern
egions only needs 2–5 million doses per year. Further, the differ-
nce in protection using one or the other formulation is not well
eﬁned [6] as this will depend on the extent to which the viruses
ave drifted.
.3.  Production of adjuvanted vaccines
Butantan considers that the best option to address potential
hortages of inﬂuenza vaccine is antigen sparing through the use
f adjuvants. We  ﬁrst intended to formulate our inﬂuenza vaccines
sing aluminium hydroxide. We  anticipated that by doing this we
ould not only be able to maximize production capacity by reduc-
ng the HA antigen content per dose, but also to lower the price of
he vaccine to make it accessible for the least developed countries.
nfortunately, results of many published animal and clinical assays,
ostly for H5N1, show that immunopotentiation by aluminium




source of aluminium salts, although the recent establishment of
the mechanism of potentiation of aluminium salts [7] should lead
to the improved performance of aluminium preparations.
Butantan’s commitment in 1985 to develop a pertussis vac-
cine that is less reactogenic than whole cell vaccine, allowed us
to develop a procedure to remove lipopolysaccharide (LPS, which
is responsible for pyrogenicity and inﬂammatory responses) from
Bordetella pertussis without damaging the bacterial ultramicro-
scopic structure or the protection of mice against intracerebral
challenge with virulent strains [4]. The resulting detoxiﬁed whole
cell diphtheria–tetanus–pertussis (DTP) vaccine – DTPlow, – was not
only safer, but could be up to ﬁfty times cheaper than that of DTaP.
Our research had further showed that removal of LPS allowed for
the puriﬁcation of MPLA, which is potentially an extremely inex-
pensive adjuvant.
5.4.  Demonstration trial
The 2009 A/H1N1 pandemic called for Butantan to take on an
additional temporary role to provide pandemic vaccine to the Min-
istry of Health by ﬁlling a large number of doses imported as bulk
product from international producers. Our proposal to vaccinate
grammar school children (7–11 years old) to prevent the spread
of seasonal inﬂuenza from schools to families was therefore cur-
tailed. We  did, however, initiate a demonstration trial among 5000
children in the São Paulo area. If results of this ambitious trial, con-
ducted following stringent international practices, corroborate the
positive impact of similar strategies [8], it might be recommended
to immunize about 1 million children in Brazil.
6.  Conclusion and plans
Technology transfer is complex. It entails a great deal of respon-
sibilities on the part of the technology provider and technical
and managerial capability on the part of the recipient. Above all,
technology transfer is a joint venture based on mutual trust and
commitment. A major objective must also be for the project to
be sustainable, which implies incorporation of new developments
into the process and, ultimately, technology independence for the
recipient.
In the future, Butantan will seek ways to increase its production
capacity in order to meet the demand for inﬂuenza vaccine, either
by improving procedures within the large production plant, or by
investigating new technologies.
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